FDA Approves New Version of Preventative HIV Drug
The FDA has approved a new drug for the prevention of HIV transmission. Descovy (emtricitabine/tenofovir alafenamide) is the second medication to be approved for PrEP, a daily program which has been highly effective in reducing the spread of HIV among people at higher risk of contracting the disease. PrEP has proven to have a success rate of over 90 percent when used as directed, on a daily basis. In 2017 alone 38,739 people were diagnosed with HIV infections. Health officials hope the newly approved treatment will be a powerful tool in lowering the number of new cases in the near future.
Full Story: CNBC